

# OUR FOOTPRINT

SOURCE: CORPORATE RESPONSIBILITY REPORT 2016-2017

9,1%

**No 1** Pharmaceutical Company in Greece  
(by market share, based on IMS data)

**Turnover**  
2017

€329,4<sub>mio</sub>

€293,1<sub>mio</sub>

**Total direct investment 2016-2017**  
(tax payments and employee wages, R&D, donations, sponsorships and social support programs, rebates and claw back)

**Return on investment**  
in the Greek Economy and Society

35%

\*Some clinical trials last more than one year

**Number of clinical trials**  
in Greece\*



**Investment in Research & Development**  
in Greece

€14,6<sub>mio</sub>

34

**Total number of patient organizations**  
supported by the company



**Total employees**  
number and men/women percentage (2017)

54,5%  
477  
45,5%

We support domestic entrepreneurship

Indirect purchases from Greek suppliers percentage 2017

95,7%

Amount invested in cooperation with Greek pharmaceutical companies

€36,5<sub>mio</sub>